Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC25A5 antisense RNA 1 (SLC25A5-AS1)
- Target
- SLC25A5-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
SLC25A5 antisense RNA 1 (SLC25A5-AS1) is a long non-coding RNA (lncRNA) transcribed in the antisense orientation to the SLC25A5 gene. It does not encode a protein but serves key regulatory roles in cancer biology[1][6]. SLC25A5-AS1 expression is downregulated in several cancer types, including gastric cancer and kidney renal clear cell carcinoma, and this reduced expression is associated with tumor progression, increased proliferation, and poor prognosis[1][2][6]. Experimental evidence suggests SLC25A5-AS1 acts as a tumor suppressor by inhibiting cell proliferation, inducing cell cycle arrest, and promoting apoptosis. Mechanistically, it modulates cancer cell behavior predominantly by acting as a competing endogenous RNA (ceRNA), sponging miR-19a-3p, thereby derepressing PTEN and inhibiting the PI3K/AKT signaling pathway[1][6]. SLC25A5-AS1 has been proposed as a candidate prognostic biomarker for gastric and kidney cancer, though there are currently no drugs that directly target it[1][2][6].
- Other names
- SLC25A5 antisense RNA 1 (non-protein coding)SLC25A5-AS1SLC25A5 antisense RNA 1
02
Biological functions
Regulation of cell proliferationInduction of apoptosisCompeting endogenous RNA (ceRNA) activityCell cycle regulationRegulation of PI3K/AKT signaling pathwayRegulation of PTEN expression
03
Disease associations
Cancer (notably gastric cancer and kidney renal clear cell carcinoma)Tumor suppression (context-dependent)Prognostic biomarker in certain cancers
04
Biomarkers
Potential prognostic biomarker for gastric cancer progression[1][6]Prognostic biomarker for overall survival in kidney renal clear cell carcinoma (KIRC)[2]Associated with tumor size, stage, and metastasis in gastric cancer[1]
Beyond the preview
Go deeper on SLC25A5 antisense RNA 1 (SLC25A5-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC25A5 antisense RNA 1 (SLC25A5-AS1).